Verzistobart is a fully human Fc-engineered IgG1 kappa antibody that binds TIM-3 on certain T cells, blocking its engagement by phosphatidylserine and galectin-9. It also triggers TIM-3 receptor internalization. It is being studied in head and neck cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
INCAGN-02390, AGEN-2390
Drug type
Monoclonal antibody
Targets
T-cell immunoglobulin and mucin domain-containing protein 3 (HAVCR2)
Mechanism
Inhibitor of T-cell immunoglobulin and mucin domain-containing protein 3 (HAVCR2)
Pathways
T-cell inhibition, tumor cell lysis by cytotoxic T cells
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.